Literature DB >> 3102055

Synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia.

E H Relyveld, B Bizzini, R Ophir, S Ben-Efraim.   

Abstract

A high dose of 4 mg/kg of daunorubicin (DAU) given in combination with immunostimulation by the P40 immunomodulatory fraction of Corynebacterium granulosum and glutaraldehyde (GA)-treated tumor cells coupled with tetanus toxoid (P40 + GA-L1210-Tet) was more effective than DAU alone for treatment of L1210 mouse leukemia. A combination of low doses of DAU (0.0625-0.25 mg/kg) and P40 + GA-L1210-Tet was more effective than either P40 + GA-L1210-Tet or DAU alone. The cured mice were resistant to challenge with a high tumorigenic dose of L1210 tumor cells. A combination of various doses of mitomycin (1-4 mg/kg) with P40 + GA-L1210-Tet was more effective than mitomycin alone and was at least as effective as P40 + GA-L1210-Tet alone. Administration of DAU (0.5-4 mg/kg) to noninoculated C57BL/6 X DBA/2 mice resulted in increase of stimulation in vitro of collected spleen cells by mitogens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102055

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  Effect of cisplatin upon expression of in vivo immune tumor resistance.

Authors:  E D Crum
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

2.  Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Authors:  Yesim Eralp; Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; John M Polo; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2004-04-07       Impact factor: 6.466

3.  Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone.

Authors:  Katia Mangano; Franca Vergalito; Santa Mammana; Andrea Mariano; Rocco De Pasquale; Antonia Meloscia; Silvia Bartollino; Germano Guerra; Ferdinando Nicoletti; Roberto Di Marco
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.